58 related articles for article (PubMed ID: 23837589)
1. Effects of Osteochondrin S and select connective tissue ribonucleinate components on human osteoclasts in vitro.
Cantley MD; Rainsford KD; Haynes DR
J Pharm Pharmacol; 2013 Aug; 65(8):1214-22. PubMed ID: 23837589
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.
Cantley MD; Fairlie DP; Bartold PM; Rainsford KD; Le GT; Lucke AJ; Holding CA; Haynes DR
J Cell Physiol; 2011 Dec; 226(12):3233-41. PubMed ID: 21344383
[TBL] [Abstract][Full Text] [Related]
3. Azithromycin suppresses human osteoclast formation and activity in vitro.
Gannon SC; Cantley MD; Haynes DR; Hirsch R; Bartold PM
J Cell Physiol; 2013 May; 228(5):1098-107. PubMed ID: 23065774
[TBL] [Abstract][Full Text] [Related]
4. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation.
Zawawi MS; Dharmapatni AA; Cantley MD; McHugh KP; Haynes DR; Crotti TN
Biochem Biophys Res Commun; 2012 Oct; 427(2):404-9. PubMed ID: 23000414
[TBL] [Abstract][Full Text] [Related]
5. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
7. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
8. Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor.
Day CJ; Kim MS; Stephens SR; Simcock WE; Aitken CJ; Nicholson GC; Morrison NA
J Cell Biochem; 2004 Feb; 91(2):303-15. PubMed ID: 14743390
[TBL] [Abstract][Full Text] [Related]
9. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
10. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin receptor regulation and responsiveness to calcitonin in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor.
Samura A; Wada S; Suda S; Iitaka M; Katayama S
Endocrinology; 2000 Oct; 141(10):3774-82. PubMed ID: 11014233
[TBL] [Abstract][Full Text] [Related]
13. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
14. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.
Grcević D; Lukić IK; Kovacić N; Ivcević S; Katavić V; Marusić A
Clin Exp Immunol; 2006 Oct; 146(1):146-58. PubMed ID: 16968409
[TBL] [Abstract][Full Text] [Related]
15. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
16. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
Ishida M; Amano S
J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
[TBL] [Abstract][Full Text] [Related]
17. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.
Kim MH; Shim KS; Kim SH
Arch Pharm Res; 2010 Mar; 33(3):457-62. PubMed ID: 20361312
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1.
Kwak HB; Yang D; Ha H; Lee JH; Kim HN; Woo ER; Lee S; Kim HH; Lee ZH
Exp Mol Med; 2006 Jun; 38(3):256-64. PubMed ID: 16819284
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]